ANDA Pre-Submission Meetings Being Considered By FDA
Designed to boost application quality, creating such meetings would be another sign of the evolution of the Office of Generic Drugs.
You may also be interested in...
FDA’s ability to avoid furloughs under sequester is not good news, OND Director John Jenkins says, but instead is a sign of severe understaffing that already existed.
Small business owners say the GDUFA facility and other fees are too expensive, especially while waiting for ANDAs to be approved, but any small business waiver is unlikely until GDUFA II.
FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.